| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 220 | 2022 | 1414 | 9.070 |
Why?
|
| Prostatectomy | 99 | 2022 | 300 | 3.930 |
Why?
|
| Prostate | 75 | 2022 | 410 | 3.910 |
Why?
|
| Adenocarcinoma | 50 | 2022 | 986 | 2.590 |
Why?
|
| Prostate-Specific Antigen | 54 | 2017 | 227 | 1.230 |
Why?
|
| Neoplasm Invasiveness | 41 | 2021 | 632 | 1.140 |
Why?
|
| Biomarkers, Tumor | 39 | 2017 | 1607 | 1.030 |
Why?
|
| Biopsy, Needle | 25 | 2021 | 207 | 0.970 |
Why?
|
| Neoplasm Recurrence, Local | 42 | 2017 | 1276 | 0.880 |
Why?
|
| Neoplasm Staging | 71 | 2017 | 1300 | 0.830 |
Why?
|
| Carcinoma, Ductal | 4 | 2020 | 12 | 0.810 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 11 | 2014 | 41 | 0.800 |
Why?
|
| Male | 259 | 2022 | 64563 | 0.770 |
Why?
|
| Carcinoma, Transitional Cell | 14 | 2014 | 160 | 0.750 |
Why?
|
| Seminal Vesicles | 17 | 2017 | 52 | 0.740 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 7 | 2020 | 70 | 0.730 |
Why?
|
| Neoplasm Grading | 11 | 2022 | 277 | 0.700 |
Why?
|
| Urinary Bladder Neoplasms | 18 | 2014 | 488 | 0.700 |
Why?
|
| Prognosis | 76 | 2021 | 4895 | 0.690 |
Why?
|
| Pathology, Surgical | 7 | 2013 | 17 | 0.680 |
Why?
|
| Immunohistochemistry | 41 | 2013 | 1607 | 0.670 |
Why?
|
| Peripheral Nerves | 7 | 2014 | 91 | 0.610 |
Why?
|
| Pathology, Clinical | 6 | 2020 | 20 | 0.610 |
Why?
|
| Humans | 289 | 2025 | 130483 | 0.600 |
Why?
|
| Aged | 136 | 2021 | 20901 | 0.600 |
Why?
|
| Middle Aged | 142 | 2021 | 28400 | 0.580 |
Why?
|
| Prostatic Hyperplasia | 13 | 2005 | 115 | 0.560 |
Why?
|
| Carcinoma | 10 | 2020 | 284 | 0.540 |
Why?
|
| Cystectomy | 11 | 2014 | 141 | 0.540 |
Why?
|
| Apoptosis | 19 | 2014 | 1842 | 0.530 |
Why?
|
| Carcinoma in Situ | 6 | 2006 | 69 | 0.510 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2016 | 20 | 0.510 |
Why?
|
| Salmonella typhimurium | 1 | 2016 | 43 | 0.500 |
Why?
|
| Disease Progression | 46 | 2017 | 2206 | 0.500 |
Why?
|
| Lymph Nodes | 11 | 2012 | 360 | 0.490 |
Why?
|
| Specimen Handling | 9 | 2013 | 145 | 0.480 |
Why?
|
| Milk | 1 | 2016 | 106 | 0.480 |
Why?
|
| Endoribonucleases | 1 | 2016 | 88 | 0.480 |
Why?
|
| Neoplasm Metastasis | 16 | 2013 | 709 | 0.460 |
Why?
|
| Lymphatic Metastasis | 25 | 2012 | 427 | 0.450 |
Why?
|
| Macrophages | 5 | 2022 | 655 | 0.450 |
Why?
|
| Genetic Therapy | 13 | 2011 | 719 | 0.450 |
Why?
|
| Watchful Waiting | 4 | 2017 | 73 | 0.430 |
Why?
|
| Urethra | 6 | 2014 | 58 | 0.420 |
Why?
|
| Precancerous Conditions | 5 | 2014 | 280 | 0.420 |
Why?
|
| Sarcosine | 1 | 2013 | 8 | 0.400 |
Why?
|
| Urinary Incontinence, Stress | 3 | 2014 | 32 | 0.390 |
Why?
|
| Predictive Value of Tests | 29 | 2020 | 2298 | 0.380 |
Why?
|
| Suburethral Slings | 2 | 2014 | 9 | 0.380 |
Why?
|
| Epithelial Cells | 1 | 2016 | 895 | 0.370 |
Why?
|
| Cadaver | 2 | 2010 | 117 | 0.340 |
Why?
|
| Terminology as Topic | 2 | 2025 | 225 | 0.340 |
Why?
|
| DNA, Neoplasm | 12 | 2005 | 286 | 0.330 |
Why?
|
| Lung Neoplasms | 8 | 2022 | 1542 | 0.310 |
Why?
|
| Adult | 84 | 2021 | 31138 | 0.310 |
Why?
|
| Multivariate Analysis | 22 | 2011 | 1377 | 0.300 |
Why?
|
| Urology | 5 | 2020 | 80 | 0.300 |
Why?
|
| Inflammation | 1 | 2016 | 1473 | 0.300 |
Why?
|
| Follow-Up Studies | 32 | 2017 | 5186 | 0.300 |
Why?
|
| Thyroid Gland | 3 | 2005 | 98 | 0.290 |
Why?
|
| Aged, 80 and over | 35 | 2021 | 6783 | 0.290 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 10 | 2010 | 1215 | 0.280 |
Why?
|
| Urogenital Neoplasms | 1 | 2008 | 11 | 0.280 |
Why?
|
| Prostatic Diseases | 2 | 1998 | 13 | 0.280 |
Why?
|
| Caveolins | 6 | 2005 | 14 | 0.270 |
Why?
|
| Ganglia, Spinal | 5 | 2006 | 65 | 0.270 |
Why?
|
| DNA | 4 | 2010 | 1419 | 0.270 |
Why?
|
| Sensitivity and Specificity | 21 | 2021 | 2106 | 0.270 |
Why?
|
| Transforming Growth Factor beta | 9 | 2006 | 454 | 0.260 |
Why?
|
| Ethics, Medical | 1 | 2010 | 398 | 0.260 |
Why?
|
| Diagnosis, Differential | 15 | 2020 | 1889 | 0.260 |
Why?
|
| Caveolin 1 | 9 | 2007 | 51 | 0.250 |
Why?
|
| Thymidine Kinase | 9 | 2006 | 90 | 0.250 |
Why?
|
| Biopsy | 19 | 2020 | 1239 | 0.250 |
Why?
|
| Pleural Neoplasms | 2 | 2018 | 82 | 0.250 |
Why?
|
| Mesothelioma | 2 | 2018 | 93 | 0.240 |
Why?
|
| Thyroid Diseases | 3 | 2005 | 28 | 0.240 |
Why?
|
| Parathyroid Diseases | 1 | 2005 | 1 | 0.240 |
Why?
|
| Testicular Neoplasms | 4 | 2008 | 111 | 0.240 |
Why?
|
| Frozen Sections | 1 | 2005 | 28 | 0.240 |
Why?
|
| Pathologists | 2 | 2023 | 27 | 0.240 |
Why?
|
| Parathyroid Glands | 1 | 2005 | 27 | 0.230 |
Why?
|
| Clitoris | 1 | 2025 | 4 | 0.230 |
Why?
|
| Thyroid Nodule | 2 | 2005 | 22 | 0.220 |
Why?
|
| Cell Adhesion Molecules | 1 | 2006 | 224 | 0.220 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 60 | 0.220 |
Why?
|
| Ploidies | 7 | 2004 | 35 | 0.210 |
Why?
|
| Reproducibility of Results | 15 | 2014 | 2919 | 0.210 |
Why?
|
| Ultrasonography | 19 | 2005 | 963 | 0.210 |
Why?
|
| Disease-Free Survival | 16 | 2010 | 900 | 0.200 |
Why?
|
| Pelvis | 3 | 2020 | 71 | 0.200 |
Why?
|
| Brachytherapy | 2 | 2003 | 86 | 0.200 |
Why?
|
| Antigens, Neoplasm | 3 | 2018 | 398 | 0.200 |
Why?
|
| Neoplasm Proteins | 6 | 2016 | 683 | 0.190 |
Why?
|
| Pathology | 3 | 2015 | 27 | 0.190 |
Why?
|
| Cell Cycle Proteins | 4 | 2010 | 714 | 0.190 |
Why?
|
| Preoperative Care | 6 | 2014 | 358 | 0.180 |
Why?
|
| Personnel Selection | 1 | 2023 | 80 | 0.180 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2001 | 9 | 0.180 |
Why?
|
| Inclusion Bodies | 2 | 1998 | 39 | 0.170 |
Why?
|
| Crystallization | 2 | 1998 | 83 | 0.170 |
Why?
|
| Transcription Factors | 5 | 2012 | 2452 | 0.170 |
Why?
|
| Cytodiagnosis | 1 | 2021 | 19 | 0.170 |
Why?
|
| Retrospective Studies | 26 | 2021 | 17622 | 0.170 |
Why?
|
| Kallikreins | 1 | 2000 | 26 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2018 | 2028 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2002 | 490 | 0.160 |
Why?
|
| Survival Analysis | 8 | 2017 | 1498 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 4 | 2007 | 229 | 0.160 |
Why?
|
| Urinary Bladder | 6 | 2010 | 219 | 0.160 |
Why?
|
| Models, Biological | 5 | 2014 | 1389 | 0.160 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2016 | 1004 | 0.160 |
Why?
|
| Lymph Node Excision | 5 | 2005 | 160 | 0.160 |
Why?
|
| Receptors, Transforming Growth Factor beta | 4 | 2004 | 106 | 0.160 |
Why?
|
| Survival Rate | 10 | 2010 | 2130 | 0.160 |
Why?
|
| Adenoviridae | 9 | 2011 | 583 | 0.160 |
Why?
|
| Endoscopy, Digestive System | 1 | 2021 | 151 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2009 | 479 | 0.160 |
Why?
|
| Muscle Fibers, Skeletal | 2 | 1997 | 101 | 0.160 |
Why?
|
| Cell Nucleus | 9 | 2011 | 569 | 0.160 |
Why?
|
| Neurites | 3 | 2006 | 44 | 0.150 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 434 | 0.150 |
Why?
|
| Combined Modality Therapy | 12 | 2008 | 1233 | 0.150 |
Why?
|
| Receptors, Interleukin-6 | 4 | 2004 | 40 | 0.150 |
Why?
|
| Tumor Microenvironment | 4 | 2022 | 699 | 0.150 |
Why?
|
| Genitalia, Female | 1 | 2019 | 44 | 0.150 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 134 | 0.150 |
Why?
|
| Urinary Tract | 1 | 2019 | 53 | 0.150 |
Why?
|
| Image Processing, Computer-Assisted | 10 | 2009 | 597 | 0.150 |
Why?
|
| Breast Neoplasms | 7 | 2007 | 2603 | 0.150 |
Why?
|
| Female | 43 | 2025 | 70322 | 0.140 |
Why?
|
| Cohort Studies | 14 | 2017 | 5072 | 0.140 |
Why?
|
| Flutamide | 3 | 2004 | 24 | 0.140 |
Why?
|
| Androgen Antagonists | 3 | 2007 | 109 | 0.140 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2007 | 463 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2005 | 599 | 0.140 |
Why?
|
| Societies, Medical | 9 | 2021 | 791 | 0.140 |
Why?
|
| Proportional Hazards Models | 13 | 2010 | 1399 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 568 | 0.140 |
Why?
|
| Anticarcinogenic Agents | 3 | 2000 | 46 | 0.140 |
Why?
|
| Cadherins | 4 | 2003 | 181 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 1 | 1999 | 253 | 0.140 |
Why?
|
| Membrane Proteins | 7 | 2013 | 1603 | 0.130 |
Why?
|
| Cattle | 2 | 2016 | 501 | 0.130 |
Why?
|
| Biopsy, Large-Core Needle | 2 | 2018 | 35 | 0.130 |
Why?
|
| Ganciclovir | 8 | 2006 | 102 | 0.130 |
Why?
|
| GPI-Linked Proteins | 1 | 2017 | 105 | 0.130 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2003 | 42 | 0.130 |
Why?
|
| RAW 264.7 Cells | 1 | 2016 | 47 | 0.130 |
Why?
|
| Salmonella Infections | 1 | 2016 | 31 | 0.120 |
Why?
|
| Salpingectomy | 1 | 2016 | 15 | 0.120 |
Why?
|
| Genes, erbB-1 | 1 | 2016 | 9 | 0.120 |
Why?
|
| Observer Variation | 5 | 2014 | 312 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 567 | 0.120 |
Why?
|
| Interleukin-6 | 3 | 2004 | 413 | 0.120 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 3 | 2013 | 64 | 0.120 |
Why?
|
| Macrophages, Alveolar | 1 | 2016 | 51 | 0.120 |
Why?
|
| Immunomodulation | 1 | 2016 | 81 | 0.120 |
Why?
|
| Calcinosis | 1 | 1998 | 180 | 0.120 |
Why?
|
| Ovariectomy | 1 | 2016 | 157 | 0.120 |
Why?
|
| Consensus | 4 | 2021 | 530 | 0.120 |
Why?
|
| Signal Transduction | 4 | 2016 | 4678 | 0.120 |
Why?
|
| Cystadenoma, Papillary | 1 | 1995 | 3 | 0.120 |
Why?
|
| Pneumonectomy | 1 | 2017 | 147 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 3 | 2007 | 50 | 0.120 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2016 | 137 | 0.120 |
Why?
|
| Isoenzymes | 4 | 2003 | 211 | 0.120 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1995 | 20 | 0.120 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 1995 | 25 | 0.120 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2003 | 323 | 0.120 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2004 | 250 | 0.120 |
Why?
|
| Hip Prosthesis | 1 | 1995 | 13 | 0.120 |
Why?
|
| Blotting, Western | 6 | 2010 | 1019 | 0.120 |
Why?
|
| Histiocytosis | 1 | 1995 | 18 | 0.110 |
Why?
|
| Lymphatic Diseases | 1 | 1995 | 28 | 0.110 |
Why?
|
| Urokinase-Type Plasminogen Activator | 2 | 2007 | 32 | 0.110 |
Why?
|
| Endarterectomy, Carotid | 1 | 2016 | 75 | 0.110 |
Why?
|
| Ki-67 Antigen | 7 | 2009 | 105 | 0.110 |
Why?
|
| Treatment Outcome | 20 | 2018 | 12874 | 0.110 |
Why?
|
| Carcinoma, Papillary | 3 | 2001 | 92 | 0.110 |
Why?
|
| DNA Methylation | 3 | 2012 | 1091 | 0.110 |
Why?
|
| Epididymis | 1 | 1995 | 64 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 2 | 2007 | 372 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 3 | 2014 | 1289 | 0.110 |
Why?
|
| DNA, Bacterial | 1 | 2016 | 482 | 0.110 |
Why?
|
| Vascular Calcification | 1 | 2016 | 70 | 0.110 |
Why?
|
| Tissue Kallikreins | 3 | 2003 | 7 | 0.110 |
Why?
|
| Animals | 22 | 2016 | 33862 | 0.110 |
Why?
|
| Mice | 15 | 2016 | 18197 | 0.110 |
Why?
|
| RNA, Neoplasm | 3 | 2006 | 127 | 0.110 |
Why?
|
| Carotid Artery Diseases | 1 | 2016 | 131 | 0.110 |
Why?
|
| Mucoproteins | 1 | 1994 | 11 | 0.110 |
Why?
|
| Hysterectomy | 1 | 2016 | 199 | 0.110 |
Why?
|
| Tissue Array Analysis | 6 | 2010 | 135 | 0.110 |
Why?
|
| Paraganglia, Chromaffin | 1 | 1994 | 1 | 0.110 |
Why?
|
| Simplexvirus | 7 | 2006 | 103 | 0.110 |
Why?
|
| Acyclovir | 2 | 2004 | 48 | 0.110 |
Why?
|
| Logistic Models | 9 | 2007 | 1803 | 0.100 |
Why?
|
| Medical Records | 2 | 2013 | 177 | 0.100 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 149 | 0.100 |
Why?
|
| Cytoplasm | 3 | 2010 | 252 | 0.100 |
Why?
|
| Antigens, CD34 | 1 | 2014 | 97 | 0.100 |
Why?
|
| Peptides | 2 | 2017 | 708 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2003 | 728 | 0.100 |
Why?
|
| Valine | 2 | 2004 | 110 | 0.100 |
Why?
|
| Professional Role | 1 | 2014 | 75 | 0.100 |
Why?
|
| Cell Line, Tumor | 7 | 2018 | 3720 | 0.100 |
Why?
|
| Stromal Cells | 6 | 2007 | 310 | 0.100 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 448 | 0.100 |
Why?
|
| Time Factors | 9 | 2007 | 6203 | 0.100 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2013 | 6 | 0.100 |
Why?
|
| Nomograms | 2 | 2010 | 40 | 0.100 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2013 | 16 | 0.100 |
Why?
|
| RNA, Messenger | 7 | 2010 | 2565 | 0.100 |
Why?
|
| Cell Communication | 3 | 2003 | 188 | 0.100 |
Why?
|
| Receptors, Cell Surface | 2 | 2007 | 420 | 0.100 |
Why?
|
| Erectile Dysfunction | 3 | 2017 | 195 | 0.100 |
Why?
|
| Coculture Techniques | 4 | 2006 | 232 | 0.090 |
Why?
|
| Databases as Topic | 1 | 2013 | 74 | 0.090 |
Why?
|
| Antiviral Agents | 8 | 2006 | 807 | 0.090 |
Why?
|
| Risk Assessment | 9 | 2017 | 3686 | 0.090 |
Why?
|
| Histocytological Preparation Techniques | 2 | 2010 | 5 | 0.090 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2003 | 63 | 0.090 |
Why?
|
| Microscopy, Electron | 3 | 1998 | 310 | 0.090 |
Why?
|
| Menorrhagia | 1 | 2013 | 77 | 0.090 |
Why?
|
| Patient Selection | 5 | 2016 | 721 | 0.090 |
Why?
|
| Palpation | 7 | 2003 | 18 | 0.090 |
Why?
|
| Genes, Suppressor | 1 | 2011 | 12 | 0.090 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2013 | 102 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2004 | 602 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 189 | 0.090 |
Why?
|
| Postoperative Period | 3 | 2007 | 330 | 0.090 |
Why?
|
| Salvage Therapy | 4 | 2003 | 175 | 0.080 |
Why?
|
| Transcriptome | 1 | 2018 | 1129 | 0.080 |
Why?
|
| Genetic Vectors | 7 | 2011 | 902 | 0.080 |
Why?
|
| ErbB Receptors | 2 | 2016 | 295 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 1079 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 417 | 0.080 |
Why?
|
| Lymphocyte Activation | 2 | 2004 | 629 | 0.080 |
Why?
|
| Tumor Burden | 4 | 2014 | 239 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 646 | 0.080 |
Why?
|
| Regression Analysis | 5 | 2007 | 759 | 0.080 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2003 | 87 | 0.080 |
Why?
|
| Thyroid Neoplasms | 3 | 1995 | 249 | 0.080 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 3 | 2005 | 32 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 1997 | 1008 | 0.080 |
Why?
|
| United States | 9 | 2023 | 11828 | 0.080 |
Why?
|
| Sural Nerve | 2 | 2001 | 46 | 0.080 |
Why?
|
| Adenoma | 3 | 2004 | 145 | 0.080 |
Why?
|
| Genes, erbB-2 | 2 | 2007 | 32 | 0.080 |
Why?
|
| Carcinoma, Small Cell | 1 | 1990 | 38 | 0.080 |
Why?
|
| Oncogenes | 1 | 2010 | 163 | 0.080 |
Why?
|
| Nuclear Proteins | 2 | 2010 | 1229 | 0.080 |
Why?
|
| Visceral Prolapse | 1 | 2009 | 1 | 0.080 |
Why?
|
| Fibroblasts | 1 | 2014 | 859 | 0.080 |
Why?
|
| Thymus Neoplasms | 1 | 1990 | 40 | 0.080 |
Why?
|
| Uterine Prolapse | 1 | 2009 | 22 | 0.080 |
Why?
|
| DNA Primers | 4 | 2007 | 606 | 0.080 |
Why?
|
| Quantum Dots | 1 | 2009 | 16 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 6 | 2010 | 236 | 0.070 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2009 | 60 | 0.070 |
Why?
|
| Metabolomics | 1 | 2013 | 504 | 0.070 |
Why?
|
| Loperamide | 1 | 2008 | 8 | 0.070 |
Why?
|
| Asbestosis | 1 | 1988 | 2 | 0.070 |
Why?
|
| Asbestos | 1 | 1988 | 11 | 0.070 |
Why?
|
| Laboratories, Hospital | 1 | 2008 | 24 | 0.070 |
Why?
|
| Boronic Acids | 1 | 2008 | 48 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 6 | 2006 | 146 | 0.070 |
Why?
|
| Pyrazines | 1 | 2008 | 79 | 0.070 |
Why?
|
| Fecal Incontinence | 1 | 2008 | 74 | 0.070 |
Why?
|
| Receptors, Androgen | 3 | 2007 | 415 | 0.070 |
Why?
|
| Mucous Membrane | 2 | 2001 | 89 | 0.070 |
Why?
|
| ROC Curve | 5 | 2017 | 606 | 0.070 |
Why?
|
| Urinary Incontinence, Urge | 1 | 2007 | 4 | 0.070 |
Why?
|
| Bronchi | 1 | 1988 | 98 | 0.070 |
Why?
|
| Histone Acetyltransferases | 1 | 2008 | 226 | 0.070 |
Why?
|
| Granulosa Cell Tumor | 1 | 2008 | 38 | 0.070 |
Why?
|
| Sputum | 1 | 1988 | 115 | 0.070 |
Why?
|
| Biological Evolution | 1 | 2009 | 222 | 0.070 |
Why?
|
| Urodynamics | 1 | 2007 | 34 | 0.070 |
Why?
|
| Cell Division | 4 | 2004 | 721 | 0.070 |
Why?
|
| Base Sequence | 4 | 2001 | 2763 | 0.070 |
Why?
|
| Probability | 6 | 2008 | 306 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2013 | 752 | 0.070 |
Why?
|
| Recovery of Function | 2 | 2007 | 443 | 0.070 |
Why?
|
| Renal Artery | 1 | 1988 | 70 | 0.070 |
Why?
|
| Histocytochemistry | 2 | 1998 | 83 | 0.070 |
Why?
|
| Analysis of Variance | 6 | 2001 | 937 | 0.070 |
Why?
|
| Aneurysm | 1 | 1988 | 66 | 0.070 |
Why?
|
| In Situ Hybridization | 6 | 2007 | 441 | 0.060 |
Why?
|
| Informed Consent | 1 | 2010 | 348 | 0.060 |
Why?
|
| Molecular Sequence Data | 3 | 2009 | 3496 | 0.060 |
Why?
|
| Systems Biology | 1 | 2007 | 60 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2003 | 783 | 0.060 |
Why?
|
| Hyperplasia | 2 | 1999 | 190 | 0.060 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2007 | 144 | 0.060 |
Why?
|
| Neurogenesis | 1 | 2008 | 217 | 0.060 |
Why?
|
| Surveys and Questionnaires | 4 | 2023 | 4004 | 0.060 |
Why?
|
| Case-Control Studies | 5 | 2011 | 3388 | 0.060 |
Why?
|
| Genome | 1 | 2009 | 463 | 0.060 |
Why?
|
| Phenotype | 3 | 2012 | 4477 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2004 | 754 | 0.060 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2003 | 29 | 0.060 |
Why?
|
| Cell Proliferation | 3 | 2010 | 2479 | 0.060 |
Why?
|
| Behavior Therapy | 1 | 2008 | 271 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2005 | 188 | 0.060 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2006 | 37 | 0.060 |
Why?
|
| Genes, p53 | 2 | 1997 | 208 | 0.060 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2018 | 124 | 0.060 |
Why?
|
| Genital Neoplasms, Male | 2 | 2003 | 9 | 0.060 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2007 | 233 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2011 | 1086 | 0.060 |
Why?
|
| Quality of Life | 3 | 2013 | 2072 | 0.060 |
Why?
|
| False Negative Reactions | 2 | 2004 | 87 | 0.060 |
Why?
|
| Obesity, Morbid | 1 | 2007 | 229 | 0.060 |
Why?
|
| Trans-Activators | 1 | 2008 | 705 | 0.060 |
Why?
|
| Neoplasms | 2 | 2014 | 2944 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 6 | 2003 | 984 | 0.050 |
Why?
|
| Risk | 3 | 2014 | 729 | 0.050 |
Why?
|
| Organ Size | 2 | 2008 | 418 | 0.050 |
Why?
|
| Adenomatoid Tumor | 1 | 2004 | 1 | 0.050 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 2001 | 3 | 0.050 |
Why?
|
| Pericardium | 1 | 2005 | 103 | 0.050 |
Why?
|
| Hemangioma | 1 | 2005 | 89 | 0.050 |
Why?
|
| DNA, Mitochondrial | 1 | 2006 | 232 | 0.050 |
Why?
|
| Paraneoplastic Endocrine Syndromes | 1 | 2004 | 5 | 0.050 |
Why?
|
| Heart Neoplasms | 1 | 2005 | 107 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2004 | 7 | 0.050 |
Why?
|
| Mutation | 2 | 2010 | 6134 | 0.050 |
Why?
|
| Research Design | 1 | 2008 | 718 | 0.050 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2004 | 15 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2004 | 88 | 0.050 |
Why?
|
| Alternative Splicing | 2 | 2009 | 311 | 0.050 |
Why?
|
| CD36 Antigens | 1 | 2004 | 35 | 0.050 |
Why?
|
| Hypercalcemia | 1 | 2004 | 41 | 0.050 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2004 | 72 | 0.050 |
Why?
|
| DNA, Complementary | 2 | 2003 | 431 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 3 | 2009 | 1717 | 0.050 |
Why?
|
| Treatment Failure | 4 | 1999 | 351 | 0.050 |
Why?
|
| Forecasting | 5 | 2005 | 353 | 0.050 |
Why?
|
| Parathyroid Hormone | 1 | 2004 | 84 | 0.050 |
Why?
|
| Amino Acid Transport System ASC | 1 | 2003 | 5 | 0.050 |
Why?
|
| Peptidylprolyl Isomerase | 1 | 2003 | 34 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2004 | 122 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2003 | 1616 | 0.050 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2003 | 19 | 0.050 |
Why?
|
| Recurrence | 4 | 2012 | 1485 | 0.050 |
Why?
|
| Proteins | 2 | 2009 | 1015 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2019 | 1223 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2003 | 157 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2002 | 58 | 0.050 |
Why?
|
| Immunoassay | 1 | 2003 | 125 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2005 | 342 | 0.050 |
Why?
|
| Patient Satisfaction | 3 | 2013 | 451 | 0.050 |
Why?
|
| Prospective Studies | 7 | 2018 | 6428 | 0.050 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2002 | 25 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 2001 | 143 | 0.050 |
Why?
|
| Aging | 2 | 2007 | 1253 | 0.050 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2002 | 13 | 0.050 |
Why?
|
| Exercise | 1 | 2008 | 859 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2008 | 767 | 0.050 |
Why?
|
| Mammography | 1 | 2003 | 124 | 0.050 |
Why?
|
| Leukemia, Hairy Cell | 1 | 1982 | 16 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2010 | 1796 | 0.050 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2003 | 108 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2004 | 140 | 0.050 |
Why?
|
| Up-Regulation | 4 | 2006 | 835 | 0.050 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2002 | 11 | 0.050 |
Why?
|
| Penile Erection | 2 | 2000 | 79 | 0.050 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2002 | 99 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 332 | 0.050 |
Why?
|
| Age Factors | 4 | 2016 | 2835 | 0.040 |
Why?
|
| Antigens, CD | 3 | 2004 | 410 | 0.040 |
Why?
|
| Endometriosis | 1 | 2004 | 160 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 813 | 0.040 |
Why?
|
| Granuloma | 1 | 1982 | 60 | 0.040 |
Why?
|
| Lipoxygenase | 1 | 2001 | 3 | 0.040 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 573 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 345 | 0.040 |
Why?
|
| Keratins | 3 | 2003 | 49 | 0.040 |
Why?
|
| Hydroxyl Radical | 1 | 2001 | 13 | 0.040 |
Why?
|
| Clinical Trials as Topic | 4 | 2007 | 1125 | 0.040 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2001 | 2 | 0.040 |
Why?
|
| Guanine | 1 | 2001 | 60 | 0.040 |
Why?
|
| Photomicrography | 1 | 2021 | 10 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2004 | 426 | 0.040 |
Why?
|
| Models, Statistical | 3 | 2014 | 482 | 0.040 |
Why?
|
| Urologists | 1 | 2021 | 11 | 0.040 |
Why?
|
| Receptors, Progesterone | 1 | 2004 | 675 | 0.040 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2021 | 22 | 0.040 |
Why?
|
| Mucins | 1 | 2021 | 69 | 0.040 |
Why?
|
| Oligospermia | 2 | 1997 | 65 | 0.040 |
Why?
|
| Epithelium | 4 | 2004 | 338 | 0.040 |
Why?
|
| Adenine | 1 | 2001 | 120 | 0.040 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 2000 | 255 | 0.040 |
Why?
|
| Algorithms | 5 | 2008 | 1681 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2006 | 85 | 0.040 |
Why?
|
| Thiazolidinediones | 1 | 2001 | 81 | 0.040 |
Why?
|
| Patient Education as Topic | 1 | 2003 | 456 | 0.040 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2002 | 222 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 266 | 0.040 |
Why?
|
| Ligaments | 1 | 2019 | 20 | 0.040 |
Why?
|
| Introns | 1 | 2000 | 281 | 0.040 |
Why?
|
| Receptors, Retinoic Acid | 1 | 2000 | 77 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2010 | 1577 | 0.040 |
Why?
|
| Spermatogenesis | 2 | 1997 | 168 | 0.040 |
Why?
|
| Internationality | 2 | 2010 | 128 | 0.040 |
Why?
|
| Risk Factors | 5 | 2006 | 10950 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 1215 | 0.040 |
Why?
|
| Activin Receptors, Type I | 1 | 1999 | 33 | 0.040 |
Why?
|
| Leptin | 1 | 2001 | 216 | 0.040 |
Why?
|
| Veins | 1 | 2019 | 96 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2000 | 172 | 0.040 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 1999 | 82 | 0.040 |
Why?
|
| Pelvic Floor | 2 | 2009 | 36 | 0.040 |
Why?
|
| Protein Precursors | 1 | 2000 | 139 | 0.040 |
Why?
|
| Actuarial Analysis | 4 | 1997 | 27 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2354 | 0.040 |
Why?
|
| Staining and Labeling | 3 | 2004 | 167 | 0.040 |
Why?
|
| Atrophy | 1 | 1999 | 244 | 0.040 |
Why?
|
| Receptors, Estrogen | 1 | 1982 | 726 | 0.040 |
Why?
|
| Prostatitis | 1 | 1998 | 19 | 0.040 |
Why?
|
| Arteries | 1 | 2019 | 210 | 0.040 |
Why?
|
| S100 Proteins | 3 | 2005 | 40 | 0.040 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2018 | 6 | 0.040 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2001 | 325 | 0.030 |
Why?
|
| Protein-Lysine 6-Oxidase | 1 | 1998 | 8 | 0.030 |
Why?
|
| Penis | 1 | 1999 | 83 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 1267 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2010 | 1456 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2016 | 694 | 0.030 |
Why?
|
| Pleura | 1 | 2018 | 27 | 0.030 |
Why?
|
| DNA Damage | 1 | 2001 | 515 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 2002 | 420 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2011 | 394 | 0.030 |
Why?
|
| Solubility | 1 | 2017 | 117 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2007 | 498 | 0.030 |
Why?
|
| Observation | 1 | 2017 | 40 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 3816 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2009 | 228 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2017 | 69 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2009 | 413 | 0.030 |
Why?
|
| Clodronic Acid | 1 | 2016 | 4 | 0.030 |
Why?
|
| Genes, Synthetic | 1 | 2016 | 13 | 0.030 |
Why?
|
| Cetuximab | 1 | 2016 | 13 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2016 | 16 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2013 | 356 | 0.030 |
Why?
|
| Proteogenomics | 1 | 2018 | 111 | 0.030 |
Why?
|
| Review Literature as Topic | 2 | 2007 | 54 | 0.030 |
Why?
|
| Incidence | 3 | 2000 | 3330 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2018 | 361 | 0.030 |
Why?
|
| Uteroglobin | 1 | 2016 | 47 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2016 | 65 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2016 | 38 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2006 | 119 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 667 | 0.030 |
Why?
|
| Point Mutation | 1 | 1997 | 334 | 0.030 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2017 | 105 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 1997 | 227 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 1996 | 68 | 0.030 |
Why?
|
| Testis | 1 | 1997 | 397 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1995 | 32 | 0.030 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 1995 | 15 | 0.030 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 2 | 2007 | 25 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 372 | 0.030 |
Why?
|
| Mice, Transgenic | 2 | 2016 | 2342 | 0.030 |
Why?
|
| Histological Techniques | 1 | 1994 | 19 | 0.030 |
Why?
|
| Cause of Death | 1 | 2017 | 503 | 0.030 |
Why?
|
| Voluntary Health Agencies | 1 | 2014 | 5 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2014 | 24 | 0.030 |
Why?
|
| International Agencies | 1 | 2014 | 28 | 0.030 |
Why?
|
| New Zealand | 1 | 2014 | 60 | 0.030 |
Why?
|
| NF-kappa B | 2 | 2008 | 442 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2018 | 357 | 0.030 |
Why?
|
| Uromodulin | 1 | 1994 | 12 | 0.030 |
Why?
|
| Infertility, Male | 1 | 1997 | 296 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1994 | 23 | 0.030 |
Why?
|
| Synaptophysin | 1 | 1994 | 18 | 0.030 |
Why?
|
| Chromogranins | 1 | 1994 | 30 | 0.030 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 786 | 0.030 |
Why?
|
| Prodrugs | 2 | 2004 | 56 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2004 | 221 | 0.030 |
Why?
|
| Individuality | 1 | 1994 | 36 | 0.030 |
Why?
|
| Antibodies | 2 | 2006 | 320 | 0.030 |
Why?
|
| Health Surveys | 1 | 2014 | 255 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2008 | 3033 | 0.020 |
Why?
|
| Dysmenorrhea | 1 | 2013 | 13 | 0.020 |
Why?
|
| Cell Survival | 2 | 2006 | 837 | 0.020 |
Why?
|
| Australasia | 1 | 2013 | 5 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2013 | 70 | 0.020 |
Why?
|
| Leuprolide | 2 | 2004 | 17 | 0.020 |
Why?
|
| Tranexamic Acid | 1 | 2013 | 31 | 0.020 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 2 | 2004 | 35 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2014 | 704 | 0.020 |
Why?
|
| Antifibrinolytic Agents | 1 | 2013 | 47 | 0.020 |
Why?
|
| Reproductive Health | 1 | 2013 | 48 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2013 | 110 | 0.020 |
Why?
|
| Rectum | 4 | 1994 | 101 | 0.020 |
Why?
|
| United Kingdom | 1 | 2013 | 255 | 0.020 |
Why?
|
| International Cooperation | 1 | 2013 | 156 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 2 | 2003 | 121 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2013 | 225 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 614 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2005 | 243 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 923 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 2001 | 235 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1994 | 503 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 300 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 2 | 2001 | 303 | 0.020 |
Why?
|
| Adolescent | 5 | 2008 | 20762 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 527 | 0.020 |
Why?
|
| Boston | 1 | 2010 | 118 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2010 | 92 | 0.020 |
Why?
|
| Cytokines | 1 | 2016 | 1335 | 0.020 |
Why?
|
| Carcinoembryonic Antigen | 1 | 1990 | 26 | 0.020 |
Why?
|
| Lung | 1 | 2018 | 1547 | 0.020 |
Why?
|
| Mucin-1 | 1 | 1990 | 34 | 0.020 |
Why?
|
| Gene Transfer Techniques | 1 | 2011 | 344 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1990 | 95 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 87 | 0.020 |
Why?
|
| Synteny | 1 | 2009 | 69 | 0.020 |
Why?
|
| Animals, Domestic | 1 | 2009 | 38 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2009 | 61 | 0.020 |
Why?
|
| Surgical Mesh | 1 | 2009 | 64 | 0.020 |
Why?
|
| Mice, Inbred C3H | 2 | 2000 | 97 | 0.020 |
Why?
|
| Cisplatin | 1 | 2010 | 274 | 0.020 |
Why?
|
| Phosphorylcholine | 1 | 2008 | 31 | 0.020 |
Why?
|
| Semaphorins | 1 | 2008 | 35 | 0.020 |
Why?
|
| Bortezomib | 1 | 2008 | 71 | 0.020 |
Why?
|
| Body Mass Index | 2 | 2007 | 1676 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 2003 | 1323 | 0.020 |
Why?
|
| Species Specificity | 1 | 2009 | 482 | 0.020 |
Why?
|
| Accreditation | 1 | 2008 | 87 | 0.020 |
Why?
|
| Patient Care Management | 1 | 2008 | 61 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 1988 | 114 | 0.020 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2007 | 3 | 0.020 |
Why?
|
| Peritoneal Dialysis, Continuous Ambulatory | 1 | 1988 | 22 | 0.020 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2007 | 2 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2009 | 265 | 0.020 |
Why?
|
| Bone Neoplasms | 2 | 2004 | 473 | 0.020 |
Why?
|
| North America | 1 | 2008 | 257 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1990 | 410 | 0.020 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1988 | 44 | 0.020 |
Why?
|
| Physicians | 1 | 2014 | 634 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 51 | 0.020 |
Why?
|
| Europe | 1 | 2008 | 366 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2003 | 2109 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 57 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2008 | 582 | 0.020 |
Why?
|
| 3-Phosphoinositide-Dependent Protein Kinases | 1 | 2007 | 18 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 561 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2007 | 51 | 0.020 |
Why?
|
| Photochemotherapy | 1 | 2007 | 40 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2008 | 258 | 0.020 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2007 | 99 | 0.020 |
Why?
|
| Mucosa-Associated Lymphoid Tissue Lymphoma Translocation 1 Protein | 1 | 2006 | 5 | 0.020 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 13 | 0.020 |
Why?
|
| Hypoxanthine Phosphoribosyltransferase | 1 | 2006 | 34 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 494 | 0.020 |
Why?
|
| Linear Models | 1 | 2008 | 688 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2017 | 3118 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2013 | 771 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 1227 | 0.020 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 2006 | 27 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2005 | 42 | 0.010 |
Why?
|
| CpG Islands | 1 | 2007 | 343 | 0.010 |
Why?
|
| Caspases | 1 | 2006 | 156 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2006 | 68 | 0.010 |
Why?
|
| Cholinesterases | 1 | 2005 | 6 | 0.010 |
Why?
|
| Neuroanatomy | 1 | 2005 | 11 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2009 | 650 | 0.010 |
Why?
|
| Histoplasmosis | 1 | 1986 | 54 | 0.010 |
Why?
|
| Colonic Neoplasms | 1 | 1988 | 267 | 0.010 |
Why?
|
| Environmental Exposure | 1 | 1988 | 289 | 0.010 |
Why?
|
| Carcinogens | 1 | 2005 | 129 | 0.010 |
Why?
|
| Gold Radioisotopes | 1 | 1985 | 2 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1985 | 4 | 0.010 |
Why?
|
| Luteal Phase | 1 | 2004 | 7 | 0.010 |
Why?
|
| Follicular Phase | 1 | 2004 | 8 | 0.010 |
Why?
|
| Tissue Culture Techniques | 1 | 2005 | 64 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2005 | 230 | 0.010 |
Why?
|
| World Health Organization | 1 | 2005 | 113 | 0.010 |
Why?
|
| Drosophila melanogaster | 1 | 2010 | 850 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 107 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2006 | 4697 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 269 | 0.010 |
Why?
|
| Genistein | 1 | 2004 | 40 | 0.010 |
Why?
|
| Avian Sarcoma Viruses | 1 | 2004 | 30 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2005 | 239 | 0.010 |
Why?
|
| Kidney | 2 | 1988 | 1283 | 0.010 |
Why?
|
| Models, Chemical | 1 | 2004 | 78 | 0.010 |
Why?
|
| Sulfones | 1 | 2004 | 72 | 0.010 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2004 | 7 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1709 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2008 | 555 | 0.010 |
Why?
|
| Parathyroid Neoplasms | 1 | 2004 | 22 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 424 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 521 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2004 | 104 | 0.010 |
Why?
|
| Desmin | 1 | 2003 | 19 | 0.010 |
Why?
|
| Nitriles | 1 | 2004 | 161 | 0.010 |
Why?
|
| NIMA-Interacting Peptidylprolyl Isomerase | 1 | 2003 | 30 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2004 | 161 | 0.010 |
Why?
|
| Physical Examination | 2 | 1994 | 160 | 0.010 |
Why?
|
| Calibration | 1 | 2003 | 92 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2003 | 39 | 0.010 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 38 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 114 | 0.010 |
Why?
|
| Rare Diseases | 1 | 2005 | 207 | 0.010 |
Why?
|
| Aortic Aneurysm | 1 | 1986 | 221 | 0.010 |
Why?
|
| Pressure | 1 | 2003 | 122 | 0.010 |
Why?
|
| Cell Differentiation | 2 | 2006 | 1927 | 0.010 |
Why?
|
| Cyclin A | 1 | 2002 | 17 | 0.010 |
Why?
|
| S-Phase Kinase-Associated Proteins | 1 | 2002 | 19 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 776 | 0.010 |
Why?
|
| Keratin-20 | 1 | 2002 | 7 | 0.010 |
Why?
|
| Keratin-7 | 1 | 2002 | 6 | 0.010 |
Why?
|
| Intermediate Filament Proteins | 1 | 2002 | 21 | 0.010 |
Why?
|
| Rabbits | 1 | 2003 | 574 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1982 | 54 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1982 | 12 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2009 | 1553 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2009 | 896 | 0.010 |
Why?
|
| Lymphatic Irradiation | 1 | 2001 | 4 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 749 | 0.010 |
Why?
|
| Leukopenia | 1 | 1982 | 45 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 174 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2004 | 266 | 0.010 |
Why?
|
| Endometrium | 1 | 2004 | 283 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1982 | 249 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2003 | 392 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2001 | 78 | 0.010 |
Why?
|
| Laminin | 1 | 2001 | 67 | 0.010 |
Why?
|
| Actins | 1 | 2003 | 315 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 2001 | 52 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2001 | 42 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2001 | 65 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1312 | 0.010 |
Why?
|
| Arachidonate 15-Lipoxygenase | 1 | 2001 | 3 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 2004 | 435 | 0.010 |
Why?
|
| Agar | 1 | 2001 | 17 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 83 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2006 | 796 | 0.010 |
Why?
|
| Biocompatible Materials | 1 | 2001 | 108 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 1685 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2002 | 254 | 0.010 |
Why?
|
| Luciferases | 1 | 2001 | 126 | 0.010 |
Why?
|
| Immunophenotyping | 1 | 2001 | 330 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2001 | 273 | 0.010 |
Why?
|
| Catalysis | 1 | 2001 | 137 | 0.010 |
Why?
|
| Culture Media | 1 | 2001 | 171 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2001 | 325 | 0.010 |
Why?
|
| Chaperonins | 1 | 2000 | 15 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2000 | 90 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 339 | 0.010 |
Why?
|
| Collagen | 1 | 2001 | 276 | 0.010 |
Why?
|
| Antigens, CD20 | 1 | 2000 | 44 | 0.010 |
Why?
|
| Thiazoles | 1 | 2001 | 111 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 2006 | 745 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1982 | 319 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2000 | 168 | 0.010 |
Why?
|
| Fenretinide | 1 | 2000 | 9 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2003 | 676 | 0.010 |
Why?
|
| Herpesviridae | 1 | 2000 | 32 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2001 | 426 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 168 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 194 | 0.010 |
Why?
|
| Body Height | 1 | 2001 | 195 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 360 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1827 | 0.010 |
Why?
|
| Defective Viruses | 1 | 1999 | 17 | 0.010 |
Why?
|
| Neoplasm, Residual | 1 | 1999 | 132 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2001 | 212 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2579 | 0.010 |
Why?
|
| Elasticity | 1 | 1998 | 94 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2006 | 3818 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2000 | 641 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2001 | 451 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1998 | 70 | 0.010 |
Why?
|
| DNA Nucleotidylexotransferase | 1 | 1996 | 7 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1996 | 22 | 0.010 |
Why?
|
| Biotin | 1 | 1996 | 40 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2003 | 1051 | 0.010 |
Why?
|
| Autonomic Nervous System | 1 | 1996 | 48 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1998 | 363 | 0.010 |
Why?
|
| Capillaries | 1 | 1996 | 65 | 0.010 |
Why?
|
| Virus Replication | 1 | 1999 | 597 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 10007 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1997 | 406 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2001 | 1391 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1995 | 65 | 0.010 |
Why?
|
| CD57 Antigens | 1 | 1995 | 5 | 0.010 |
Why?
|
| Thyroiditis, Autoimmune | 1 | 1995 | 9 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2001 | 1167 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1995 | 17 | 0.010 |
Why?
|
| Testosterone | 1 | 2001 | 590 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1997 | 813 | 0.010 |
Why?
|
| Genetic Markers | 1 | 1995 | 597 | 0.010 |
Why?
|
| Mitosis | 1 | 1994 | 194 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1995 | 788 | 0.010 |
Why?
|
| Exons | 1 | 1995 | 765 | 0.010 |
Why?
|
| Cerebellar Neoplasms | 1 | 1995 | 328 | 0.010 |
Why?
|
| Remission Induction | 1 | 1992 | 301 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2000 | 4660 | 0.000 |
Why?
|
| Mass Screening | 1 | 1994 | 806 | 0.000 |
Why?
|
| Texas | 1 | 1996 | 3626 | 0.000 |
Why?
|
| Aorta, Abdominal | 1 | 1986 | 95 | 0.000 |
Why?
|
| Child | 1 | 2005 | 26168 | 0.000 |
Why?
|
| Kidney Failure, Chronic | 1 | 1988 | 941 | 0.000 |
Why?
|